The goal of these CD40 targeted therapies, which include agonistic CD40 antibodies, bispecific antibodies with CD40 as one of the targets, and adenoviral vectors that increase CD40L expression, is to evoke a primarily tumor-specific T cell response [1, 2, 6, 7]. This evidence concerns the gene CD40 and neoplasm.